Basalzellkarzinom: A Phase I, open label, single arm, single center study to evaluate mechanism of action of Talimogene Laherparepvec (T-VEC, gene modified HSV-1) in locally advanced non-melanoma skin cancer

Stadium/Indikation inkl. Kurzinfo

Lymphom / BCC

Fortgeschrittenes BCC, Plattenepithel-karzinom, kutanes Lymphom, Merkelzell-karzinom

Intraläsionale T-VEC Therapie

Kurztitel

IIT T-VEC in non-melanoma skin cancer 20139157
NCT03458117

Offizieller Titel

A Phase I, open label, single arm, single center study to evaluate mechanism of action of Talimogene Laherparepvec (T-VEC, gene modified HSV-1) in locally advanced non-melanoma skin cancer.